EMEA: Concept paper on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use
Unwanted immunogenicity is a significant problem with therapeutic biologicals. The clinical problems associated with unwanted immunogenicity vary in nature and incidence. The importance of the unwanted immunogenicity problem has led to the preparation and adoption of the ‘Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins’ by the CHMP (adopted April 2008).
The source of the news: http://www.emea.europa.eu/pdfs/human/biosimilar/11472009en.pdf